Stent choice in primary percutaneous coronary intervention: Drug-eluting stents or bare metal stents?

Journal of Cardiovascular Medicine

Volumn 10, Issue SUPPL. A, 2009, Pages

  Valgimigli, Marco ^a   Airoldi, Flavio ^b   Zimarino, Marco ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Dual antiplatelet therapy; Restenosis; Target vessel revascularization; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; PANTOPRAZOLE; RAPAMYCIN; TIROFIBAN; WARFARIN; ANTITHROMBOCYTIC AGENT; METAL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BARE METAL STENT; BLEEDING; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONFERENCE PAPER; DEATH; DRUG ABSORPTION; DRUG COST; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTIVE SURGERY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MONOTHERAPY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THERAPY EFFECT; THROMBOGENESIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; EVIDENCE BASED MEDICINE; INSTRUMENTATION; MORTALITY; PATIENT SELECTION; PROSTHESIS; REVIEW; RISK ASSESSMENT; STENT; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK ASSESSMENT; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73949149586     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000362040.25767.f5     Document Type: Conference Paper

References (36)

1. Campo G, Saia F, Percoco G, Manari A, Santarelli A, Vignali L, et al. Longterm outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction Data from the REAL Registry. Int J Cardiol 2008;.
2. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-966. (Pubitemid 34983245)
3. Kawashima A, Ueda K, Nishida Y, et al. Quantitative angiographic analysis of restenosis of primary stenting using Wiktor stent for acute myocardial infarction: results from a multicenter randomized PRISAM study (abstr.). Circulation 1999; 100 (Suppl I):I-856.
4. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998; 31:1234-1239.
5. Suryapranata H, De Luca G, van't Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart 2005; 91:641-645.
6. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293:2109-2117.
7. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355:1093-1104.
8. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355:1105-1113.
9. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299:1788-1799.
10. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 2008; 156:44-56.
11. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F,Montalescot G, et al. Mortality following placement of drug-eluting and bare-metal stents for STsegment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30:321-329.
12. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, et al. Longterm clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008; 118:1817-1827.
13. Spaulding C. Four-year follow-up of the TYPHOON study: a randomized trial comparing the sirolimus-eluting stent to bare-metal stents during PCI for acute myocardial infarction. Barcelona, Spain: EuroPCR; 2009.
14. van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51:618-626.
15. Zimarino M, De Caterina R. Drug-eluting balloons for percutaneous coronary interventions. Thromb Haemost 2009; 101:9-11.
16. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000; 86:6H-11H.
17. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112:270-278.
18. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020-1029.
19. De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28:880-913.
20. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967-1971.
21. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126-2130.
22. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113:1108-1113.
23. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008; 156:141-147.
24. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009; 53:1677-1689.
25. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005; 111:1619-1626.
26. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drugeluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 2007; 50:573-583.
27. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Kobayashi Y, et al. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2003; 42:1900-1905.
28. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008; 118:1138-1145.
29. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J 2004; 25:720-722.
30. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
31. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
32. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159-e241.
33. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
34. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375.
35. Guagliumi G, Costa M, Musumeci G, Trivisonno A, Matiashvili A, Lortkipanidze N, et al. Long-term strut coverage of paclitaxel eluting stents compared with bare-metal stents implanted during primary PCI in acute myocardial infarction: a prospective, randomized, controlled study performed with optical coherence tomography. HORIZONS-OCT [abstract 3017]. Circulation 2008; 118:2315.
36. Maehara A. Vascular responses after paclitaxel-eluting stents in acute myocardial infarction: results of the HORIZONS-AMI IVUS substudy. Available online from: http://www.acc.org/media/acc-scientific- session-09/press/sunday/ i2Maehara-2.pdf. American College of Cardiology Annual Meeting. Orlando, FL, 29-31 March 2009 [Abstract]. Accessed: July 2009.